276 related articles for article (PubMed ID: 33674910)
1. Molecular pathology of thymomas: implications for diagnosis and therapy.
Marx A; Belharazem D; Lee DH; Popovic ZV; Reißfelder C; Schalke B; Schölch S; Ströbel P; Weis CA; Yamada Y
Virchows Arch; 2021 Jan; 478(1):101-110. PubMed ID: 33674910
[TBL] [Abstract][Full Text] [Related]
2. Thymoma Associated Myasthenia Gravis (TAMG): Differential Expression of Functional Pathways in Relation to MG Status in Different Thymoma Histotypes.
Yamada Y; Weis CA; Thelen J; Sticht C; Schalke B; Ströbel P; Marx A
Front Immunol; 2020; 11():664. PubMed ID: 32373124
[TBL] [Abstract][Full Text] [Related]
3. Metaplastic thymoma: a distinctive thymic neoplasm characterized by YAP1-MAML2 gene fusions.
Vivero M; Davineni P; Nardi V; Chan JKC; Sholl LM
Mod Pathol; 2020 Apr; 33(4):560-565. PubMed ID: 31641231
[TBL] [Abstract][Full Text] [Related]
4. Loss of YAP1 C-terminus expression as an ancillary marker for metaplastic thymoma: a potential pitfall in detecting YAP1::MAML2 gene rearrangement.
Wang X; Liu LL; Li Q; Xia QY; Li R; Ye SB; Zhang RS; Fang R; Chen H; Wu N; Rao Q
Histopathology; 2023 Nov; 83(5):798-809. PubMed ID: 37565303
[TBL] [Abstract][Full Text] [Related]
5. GTF2I Mutation in Thymomas: Independence From Racial-Ethnic Backgrounds. An Indian/German Comparative Study.
Jain D; Guleria P; Singh V; Parshad R; Kumar S; Gaiser T; Kurz KS; Ott G; Porubsky S; Preissler G; Sauer CG; Schölch S; Ströbel P; Hielscher T; Marx A; Popovic ZV
Pathol Oncol Res; 2021; 27():1609858. PubMed ID: 34497477
[TBL] [Abstract][Full Text] [Related]
6. Unique correlation between GTF2I mutation and spindle cell morphology in thymomas (type A and AB thymomas).
Wells K; Lamrca A; Papaxoinis G; Wallace A; Quinn AM; Summers Y; Nonaka D
J Clin Pathol; 2023 Jul; 76(7):463-466. PubMed ID: 35039450
[TBL] [Abstract][Full Text] [Related]
7. Expression patterns for Bcl-2, EMA, β-catenin, E-cadherin, PAX8, and MIB1 in thymomas.
Suster D; Miller JA; Pihan G; Mackinnon AC; Suster S
Mod Pathol; 2021 Oct; 34(10):1831-1838. PubMed ID: 34135467
[TBL] [Abstract][Full Text] [Related]
8. [Thymomas].
Marx A; Weis CA; Ströbel P
Pathologe; 2016 Sep; 37(5):412-24. PubMed ID: 27558364
[TBL] [Abstract][Full Text] [Related]
9.
Bille A; Fryer K; Wallace A; Nonaka D
J Clin Pathol; 2024 Jan; 77(2):125-127. PubMed ID: 36600564
[TBL] [Abstract][Full Text] [Related]
10. Argyrophilic nucleolar organizer regions in cells of thymoma and thymic carcinoma: correlation with DNA ploidy and clinicopathologic characteristics.
Lee YC; Chern JH; Pan CC; Chang SC; Perng RP
Chest; 1999 Apr; 115(4):1115-9. PubMed ID: 10208217
[TBL] [Abstract][Full Text] [Related]
11. Pathological Findings in Myasthenia Gravis Patients with Thymic Hyperplasia and Thymoma.
Chen P; Wang YP; Mou DL; Li ZY; Qu QM; Wang HY; Deng Y; Li XF; Wang T; Xu XH; Zhao G
Pathol Oncol Res; 2018 Jan; 24(1):67-74. PubMed ID: 28299711
[TBL] [Abstract][Full Text] [Related]
12. Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas.
Inoue M; Starostik P; Zettl A; Ströbel P; Schwarz S; Scaravilli F; Henry K; Willcox N; Müller-Hermelink HK; Marx A
Cancer Res; 2003 Jul; 63(13):3708-15. PubMed ID: 12839963
[TBL] [Abstract][Full Text] [Related]
13. Vascular architecture as a diagnostic marker for differentiation of World Health Organization thymoma subtypes and thymic carcinoma.
Pfister F; Hussain H; Belharazem D; Busch S; Simon-Keller K; Becker D; Pfister E; Rieker R; Ströbel P; Marx A
Histopathology; 2017 Apr; 70(5):693-703. PubMed ID: 27791295
[TBL] [Abstract][Full Text] [Related]
14. High expression of KITLG is a new hallmark activating the MAPK pathway in type A and AB thymoma.
Yang Z; Liu S; Wang Y; Chen Y; Zhang P; Liu Y; Zhang H; Zhang P; Tao Z; Xiong K
Thorac Cancer; 2020 Jul; 11(7):1944-1954. PubMed ID: 32463597
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature.
Guleria P; Husain N; Shukla S; Kumar S; Parshad R; Jain D
Ann Diagn Pathol; 2018 Jun; 34():135-141. PubMed ID: 29661720
[TBL] [Abstract][Full Text] [Related]
16. Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
Yoh K; Nishiwaki Y; Ishii G; Goto K; Kubota K; Ohmatsu H; Niho S; Nagai K; Saijo N
Lung Cancer; 2008 Dec; 62(3):316-20. PubMed ID: 18448188
[TBL] [Abstract][Full Text] [Related]
17. p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma.
Hirabayashi H; Fujii Y; Sakaguchi M; Tanaka H; Yoon HE; Komoto Y; Inoue M; Miyoshi S; Matsuda H
Int J Cancer; 1997 Nov; 73(5):639-44. PubMed ID: 9398039
[TBL] [Abstract][Full Text] [Related]
18. D2-40 Antibody is a Specific Marker for B2 Thymomas.
Szolkowska M; Langfort R; Winiarski S; Rudzinski P; Giedronowicz D; Szczepulska-Wojcik E; Ronduda P; Maksymiuk B; Orlowski T
Appl Immunohistochem Mol Morphol; 2017 Jul; 25(6):445-449. PubMed ID: 26808132
[TBL] [Abstract][Full Text] [Related]
19. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas.
Meister M; Schirmacher P; Dienemann H; Mechtersheimer G; Schnabel PA; Kern MA; Herpel E; Xu EC; Muley T; Thomas M; Rieker RJ
Cancer Lett; 2007 Apr; 248(2):186-91. PubMed ID: 16919868
[TBL] [Abstract][Full Text] [Related]
20. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors.
Suzuki E; Sasaki H; Kawano O; Endo K; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Jpn J Clin Oncol; 2006 Jun; 36(6):351-6. PubMed ID: 16762968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
